

# Metabolic Disorders Therapeutics-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/MCCDC46635BEN.html>

Date: January 2018

Pages: 139

Price: US\$ 3,480.00 (Single User License)

ID: MCCDC46635BEN

## Abstracts

### Report Summary

Metabolic Disorders Therapeutics-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Metabolic Disorders Therapeutics industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Metabolic Disorders Therapeutics 2013-2017, and development forecast 2018-2023

Main market players of Metabolic Disorders Therapeutics in Europe, with company and product introduction, position in the Metabolic Disorders Therapeutics market  
Market status and development trend of Metabolic Disorders Therapeutics by types and applications

Cost and profit status of Metabolic Disorders Therapeutics, and marketing status

Market growth drivers and challenges

The report segments the Europe Metabolic Disorders Therapeutics market as:

Europe Metabolic Disorders Therapeutics Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Metabolic Disorders Therapeutics Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Metachromatic Leukodystrophy

Globoid Leukodystrophy

Hepatic Encephalopathy

Others

Europe Metabolic Disorders Therapeutics Market: Application Segment Analysis  
(Consumption Volume and Market Share 2013-2023; Downstream Customers and  
Market Analysis)

Diabetes

Obesity

Hypercholesterolemia

Lysosomal storage diseases

Europe Metabolic Disorders Therapeutics Market: Players Segment Analysis (Company  
and Product introduction, Metabolic Disorders Therapeutics Sales Volume, Revenue,  
Price and Gross Margin):

Novo Nordisk

Sanofi

Merck

AstraZeneca

Eli Lilly

AbbVie

Actelion Pharmaceuticals

Adocia

Aegerion Pharmaceuticals

Akros Pharma

Alnylam Pharmaceuticals

Amarin

Amicus Therapeutics

Biopharma  
Arena Pharmaceuticals  
Astellas Pharma  
Bionaturis  
Diasome Pharmaceuticals  
Lexicon Pharmaceuticals  
Ligand Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF METABOLIC DISORDERS THERAPEUTICS**

- 1.1 Definition of Metabolic Disorders Therapeutics in This Report
- 1.2 Commercial Types of Metabolic Disorders Therapeutics
  - 1.2.1 Metachromatic Leukodystrophy
  - 1.2.2 Globoid Leukodystrophy
  - 1.2.3 Hepatic Encephalopathy
  - 1.2.4 Others
- 1.3 Downstream Application of Metabolic Disorders Therapeutics
  - 1.3.1 Diabetes
  - 1.3.2 Obesity
  - 1.3.3 Hypercholesterolemia
  - 1.3.4 Lysosomal storage diseases
- 1.4 Development History of Metabolic Disorders Therapeutics
- 1.5 Market Status and Trend of Metabolic Disorders Therapeutics 2013-2023
  - 1.5.1 Europe Metabolic Disorders Therapeutics Market Status and Trend 2013-2023
  - 1.5.2 Regional Metabolic Disorders Therapeutics Market Status and Trend 2013-2023

### **CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Metabolic Disorders Therapeutics in Europe 2013-2017
- 2.2 Consumption Market of Metabolic Disorders Therapeutics in Europe by Regions
  - 2.2.1 Consumption Volume of Metabolic Disorders Therapeutics in Europe by Regions
  - 2.2.2 Revenue of Metabolic Disorders Therapeutics in Europe by Regions
- 2.3 Market Analysis of Metabolic Disorders Therapeutics in Europe by Regions
  - 2.3.1 Market Analysis of Metabolic Disorders Therapeutics in Germany 2013-2017
  - 2.3.2 Market Analysis of Metabolic Disorders Therapeutics in United Kingdom 2013-2017
  - 2.3.3 Market Analysis of Metabolic Disorders Therapeutics in France 2013-2017
  - 2.3.4 Market Analysis of Metabolic Disorders Therapeutics in Italy 2013-2017
  - 2.3.5 Market Analysis of Metabolic Disorders Therapeutics in Spain 2013-2017
  - 2.3.6 Market Analysis of Metabolic Disorders Therapeutics in Benelux 2013-2017
  - 2.3.7 Market Analysis of Metabolic Disorders Therapeutics in Russia 2013-2017
- 2.4 Market Development Forecast of Metabolic Disorders Therapeutics in Europe 2018-2023
  - 2.4.1 Market Development Forecast of Metabolic Disorders Therapeutics in Europe 2018-2023

## 2.4.2 Market Development Forecast of Metabolic Disorders Therapeutics by Regions 2018-2023

### **CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES**

#### 3.1 Whole Europe Market Status by Types

##### 3.1.1 Consumption Volume of Metabolic Disorders Therapeutics in Europe by Types

##### 3.1.2 Revenue of Metabolic Disorders Therapeutics in Europe by Types

#### 3.2 Europe Market Status by Types in Major Countries

##### 3.2.1 Market Status by Types in Germany

##### 3.2.2 Market Status by Types in United Kingdom

##### 3.2.3 Market Status by Types in France

##### 3.2.4 Market Status by Types in Italy

##### 3.2.5 Market Status by Types in Spain

##### 3.2.6 Market Status by Types in Benelux

##### 3.2.7 Market Status by Types in Russia

#### 3.3 Market Forecast of Metabolic Disorders Therapeutics in Europe by Types

### **CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

#### 4.1 Demand Volume of Metabolic Disorders Therapeutics in Europe by Downstream Industry

#### 4.2 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Major Countries

##### 4.2.1 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Germany

##### 4.2.2 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in United Kingdom

##### 4.2.3 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in France

##### 4.2.4 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Italy

##### 4.2.5 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Spain

##### 4.2.6 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Benelux

##### 4.2.7 Demand Volume of Metabolic Disorders Therapeutics by Downstream Industry in Russia

#### 4.3 Market Forecast of Metabolic Disorders Therapeutics in Europe by Downstream Industry

### **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF METABOLIC DISORDERS THERAPEUTICS**

#### 5.1 Europe Economy Situation and Trend Overview

#### 5.2 Metabolic Disorders Therapeutics Downstream Industry Situation and Trend Overview

### **CHAPTER 6 METABOLIC DISORDERS THERAPEUTICS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE**

#### 6.1 Sales Volume of Metabolic Disorders Therapeutics in Europe by Major Players

#### 6.2 Revenue of Metabolic Disorders Therapeutics in Europe by Major Players

#### 6.3 Basic Information of Metabolic Disorders Therapeutics by Major Players

##### 6.3.1 Headquarters Location and Established Time of Metabolic Disorders Therapeutics Major Players

##### 6.3.2 Employees and Revenue Level of Metabolic Disorders Therapeutics Major Players

#### 6.4 Market Competition News and Trend

##### 6.4.1 Merger, Consolidation or Acquisition News

##### 6.4.2 Investment or Disinvestment News

##### 6.4.3 New Product Development and Launch

### **CHAPTER 7 METABOLIC DISORDERS THERAPEUTICS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

#### 7.1 Novo Nordisk

##### 7.1.1 Company profile

##### 7.1.2 Representative Metabolic Disorders Therapeutics Product

##### 7.1.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Novo Nordisk

#### 7.2 Sanofi

##### 7.2.1 Company profile

##### 7.2.2 Representative Metabolic Disorders Therapeutics Product

##### 7.2.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Sanofi

#### 7.3 Merck

- 7.3.1 Company profile
- 7.3.2 Representative Metabolic Disorders Therapeutics Product
- 7.3.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Merck
- 7.4 AstraZeneca
  - 7.4.1 Company profile
  - 7.4.2 Representative Metabolic Disorders Therapeutics Product
  - 7.4.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of AstraZeneca
- 7.5 Eli Lilly
  - 7.5.1 Company profile
  - 7.5.2 Representative Metabolic Disorders Therapeutics Product
  - 7.5.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.6 AbbVie
  - 7.6.1 Company profile
  - 7.6.2 Representative Metabolic Disorders Therapeutics Product
  - 7.6.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of AbbVie
- 7.7 Actelion Pharmaceuticals
  - 7.7.1 Company profile
  - 7.7.2 Representative Metabolic Disorders Therapeutics Product
  - 7.7.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Actelion Pharmaceuticals
- 7.8 Adocia
  - 7.8.1 Company profile
  - 7.8.2 Representative Metabolic Disorders Therapeutics Product
  - 7.8.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Adocia
- 7.9 Aegerion Pharmaceuticals
  - 7.9.1 Company profile
  - 7.9.2 Representative Metabolic Disorders Therapeutics Product
  - 7.9.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Aegerion Pharmaceuticals
- 7.10 Akros Pharma
  - 7.10.1 Company profile
  - 7.10.2 Representative Metabolic Disorders Therapeutics Product
  - 7.10.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Akros Pharma

## 7.11 Alnylam Pharmaceuticals

### 7.11.1 Company profile

### 7.11.2 Representative Metabolic Disorders Therapeutics Product

### 7.11.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Alnylam Pharmaceuticals

## 7.12 Amarin

### 7.12.1 Company profile

### 7.12.2 Representative Metabolic Disorders Therapeutics Product

### 7.12.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Amarin

## 7.13 Amicus Therapeutics

### 7.13.1 Company profile

### 7.13.2 Representative Metabolic Disorders Therapeutics Product

### 7.13.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Amicus Therapeutics

## 7.14 Biopharma

### 7.14.1 Company profile

### 7.14.2 Representative Metabolic Disorders Therapeutics Product

### 7.14.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Biopharma

## 7.15 Arena Pharmaceuticals

### 7.15.1 Company profile

### 7.15.2 Representative Metabolic Disorders Therapeutics Product

### 7.15.3 Metabolic Disorders Therapeutics Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals

## 7.16 Astellas Pharma

## 7.17 Bionaturis

## 7.18 Diasome Pharmaceuticals

## 7.19 Lexicon Pharmaceuticals

## 7.20 Ligand Pharmaceuticals

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF METABOLIC DISORDERS THERAPEUTICS**

### 8.1 Industry Chain of Metabolic Disorders Therapeutics

### 8.2 Upstream Market and Representative Companies Analysis

### 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF METABOLIC DISORDERS**



## **THERAPEUTICS**

- 9.1 Cost Structure Analysis of Metabolic Disorders Therapeutics
- 9.2 Raw Materials Cost Analysis of Metabolic Disorders Therapeutics
- 9.3 Labor Cost Analysis of Metabolic Disorders Therapeutics
- 9.4 Manufacturing Expenses Analysis of Metabolic Disorders Therapeutics

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF METABOLIC DISORDERS THERAPEUTICS**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Metabolic Disorders Therapeutics-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/MCCDC46635BEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MCCDC46635BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970